Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease a pooled analysis

JAMA Neurology

Volumn 72, Issue 1, 2015, Pages 58-65

  Agalliu, Ilir ^a   San Luciano, Marta ^b   MirelmanMD, Anat ^c   Giladi, Nir ^c,d   Waro, Bjorg ^e,f   Aasly, Jan ^e,f   Inzelberg, Rivka ^d,g   Hassin Baer, Sharon ^d,g   Friedman, Eitan ^d,g   Ruiz Martinez, Javier ^h,i,j   Marti Masso, Jose Felix ^h,i,j   Orr Urtreger, Avi ^c,d   Bressman, Susan ^a,k,l   Saunders Pullman, Rachel ^a,k,l  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^f NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^g SHEBA MEDICAL CENTER   (Israel)

^h UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

ⁱ HOSPITAL DONOSTIA   (Spain)

^j CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^k BETH ISRAEL MEDICAL CENTER   (United States)

^l MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DJ 1 PROTEIN; LEUCINE RICH REPEAT KINASE 2; PARKIN; GLYCINE; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ARTICLE; ASHKENAZI JEW; BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; COLON CANCER; CONTROLLED STUDY; ETHNICITY; EUROPE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HEMATOLOGIC MALIGNANCY; HETEROZYGOTE; HUMAN; ISRAEL; KIDNEY CANCER; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MENINGIOMA; NEOPLASM; NORWAY; OVARY CANCER; PARKINSON DISEASE; PREVALENCE; PROSTATE CANCER; SENSITIVITY ANALYSIS; SEPHARDIC JEW; SEX DIFFERENCE; SKIN CANCER; SMOKING; SPAIN; UNITED STATES; AGED; CLASSIFICATION; CLINICAL TRIAL; COMPLICATION; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MULTICENTER STUDY; MUTATION; ODDS RATIO; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; EUROPE; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLYCINE; HUMANS; ISRAEL; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; ODDS RATIO; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SENSITIVITY AND SPECIFICITY; SEX FACTORS; UNITED STATES;

EID: 84921044518     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.1973     Document Type: Article

References (36)

1. Devine MJ, Plun-Favreau H, Wood NW. Parkinson's disease and cancer: two wars, one front. Nat Rev Cancer. 2011;11(11):812-823.
2. Skibba JL, Pinckley J, Gilbert EF, Johnson RO. Multiple primary melanoma following administration of levodopa. Arch Pathol. 1972;93 (6):556-561.
3. Pan T, Zhu J, Hwu WJ, Jankovic J. The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells. PLoS One. 2012;7 (9):e45183. doi:10.1371/journal.pone.0045183.
4. Inzelberg R, Rabey JM, Melamed E, et al. High prevalence of malignant melanoma in Israeli patients with Parkinson's disease. J Neural Transm. 2011;118(8):1199-1207.
5. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Møller H. Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer. 2005;92(1):201-205.
6. Rugbjerg K, Friis S, Lassen CF, Ritz B, Olsen JH. Malignant melanoma, breast cancer and other cancers in patients with Parkinson's disease. Int J Cancer. 2012;131(8):1904-1911.
7. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Family history of melanoma and Parkinson disease risk. Neurology. 2009;73(16): 1286-1291.
8. Kareus SA, Figueroa KP, Cannon-Albright LA, Pulst SM. Shared predispositions of parkinsonism and cancer: a population-based pedigree-linked study. Arch Neurol. 2012;69(12):1572-1577.
9. Liu R, Gao X, Lu Y, Chen H. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology. 2011;76(23):2002-2009.
10. Bajaj A, Driver JA, Schernhammer ES. Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control. 2010;21(5):697-707.
11. Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers? Neurology. 2007;69(15):1542-1550.
12. Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S. Mortality and cancer incidence in patients with Parkinson's disease. J Neurol. 2000; 247(6):429-434.
13. Hernán MA, Takkouche B, Caamaño-Isorna F, Gestal-Otero JJ. Ameta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol. 2002;52(3):276-284.
14. Garber K. Parkinson's disease and cancer: the unexplored connection. J Natl Cancer Inst. 2010; 102(6):371-374.
15. West AB, Moore DJ, Biskup S, et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A. 2005;102(46):16842-16847.
16. Zheng B, Jeong JH, Asara JM, et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell. 2009;33(2):237-247.
17. Clark LN,Wang Y, Karlins E, et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology. 2006;67(10):1786-1791.
18. Sierra M, González-Aramburu I, Sánchez-Juan P, et al. High frequency and reduced penetrance of LRRK2 G2019S mutation among Parkinson's disease patients in Cantabria (Spain). Mov Disord. 2011;26 (13):2343-2346.
19. Inzelberg R, Cohen OS, Aharon-Peretz J, et al. The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology. 2012;78(11):781-786.
20. Saunders-Pullman R, Barrett MJ, Stanley KM, et al. LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease. Mov Disord. 2010;25(15):2536-2541.
21. Strongosky AJ, Farrer M,Wszolek ZK. Are Parkinson disease patients protected from some but not all cancers? Neurology. 2008;71(20):1650-1651.
22. Ruiz-Martínez J, de la Riva P, Rodríguez-Oroz MC, et al. Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2. Mov Disord. 2014;29(6):750-755.
23. Orr-Urtreger A, Shifrin C, Rozovski U, et al. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology. 2007;69(16):1595-1602.
24. Gan-Or Z, Bar-Shira A, Mirelman A, et al. LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease. Neurogenetics. 2010;11(1):121-125.
25. Breslow NE, Day NE. The Analysis of Case-Control Studies. Lyon: International Agency for Research on Cancer; 1980.
26. Kleinbaum DG, Kupper LK, Nizam A, Muller KE. Applied Regression Analysis and Other Multivariable Methods. 4th ed. Belmont, CA: Thompson; 2007.
27. SmithWW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci. 2006;9 (10):1231-1233.
28. Liou GY, Gallo KA. New biochemical approaches towards understanding the Parkinson's disease-associated kinase, LRRK2. Biochem J. 2009;424(1):e1-e3. doi:10.1042/BJ20091540.
29. Looyenga BD, Furge KA, Dykema KJ, et al. Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proc Natl Acad Sci U S A. 2011;108(4):1439-1444.
30. Mortiboys H, Cox A, Brock IW, Bandmann O. The common PARK8 mutation LRRK2G2019S is not a risk factor for breast cancer in the absence of Parkinson's disease. J Neurol. 2013;260(8):2177-2178.
31. Kravitz E, Laitman Y, Hassin-Baer S, Inzelberg R, Friedman E. Parkinson's disease genes do not segregate with breast cancer genes' loci. Cancer Epidemiol Biomarkers Prev. 2013;22(8):1464-1472.
32. Ragonese P, D'Amelio M, Callari G, Salemi G, Morgante L, Savettieri G. Age at menopause predicts age at onset of Parkinson's disease. Mov Disord. 2006;21(12):2211-2214.
33. Ragonese P, D'Amelio M, Salemi G, et al. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology. 2004;62(11):2010-2014.
34. Ragonese P, D'Amelio M, Savettieri G. Implications for estrogens in Parkinson's disease: an epidemiological approach. Ann N Y Acad Sci. 2006; 1089:373-382.
35. Mistry PK, Taddei T, vom Dahl S, Rosenbloom BE. Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism. Crit Rev Oncog. 2013;18(3):235-246.
36. Cormand B, Grinberg D, Gort L, Chabás A, Vilageliu L. Molecular analysis and clinical findings in the Spanish Gaucher disease population: putative haplotype of the N370S ancestral chromosome. Hum Mutat. 1998;11(4):295-305.